Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York
Professor of Medicine
Department of Medicine
Duke University School of Medicine
Member, Duke Cancer Institute
Durham, North Carolina
Assistant Professor of Medicine (Oncology)
Leader, Endocrine Cancers Research Group
Stanford Cancer Institute
Stanford University
Stanford, California
Senior Clinical Editor
Editorial Contributor
Associate Scientific Director
Scientific Director
Associate Director, Scientific Services
Associate Director, Educational Strategy
Senior Director, Educational Strategy
Director, CME Program Development
Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana
This program is intended for community medical oncologists, nurses, pharmacists, and other HCPs who treat and manage patients with NTRK- and RET-altered malignancies.
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-153-H01-P.
Type of Activity: Application
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 10, 2022, through June 09, 2023:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate.
After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page.
Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)
Commentary from Dr Heather McArthur on latest developments in managing early-stage breast cancer (EBC), from Clinical Care Options (CCO)
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.
Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.